A clinical trial conducted in sub-Saharan African countries over 3 years, has revealed a candidate vaccine for tackling tuberculosis. The candidate vaccine, M72/AS01E, was reported to be 54% effective at preventing active pulmonary tuberculosis disease.
Take a look at this month’s industry headlines including US FDA approvals for XOFLUZATM and a rapid diagnostic test for…
Researchers from Gladstone Institutes and their partners at Xyphos Biosciences have demonstrated that a cell-based therapy, convertibleCAR®, appears to reduce the latent HIV reservoir in individuals on antiretroviral therapy.
An independent commission of experts concluded that wild type poliovirus type 3 (WPV3) has been eradicated worldwide, representing a historic achievement.
Researchers from the University Medical Center Groningen and the Maastricht University Medical Center have discovered how commonly used drugs affect the composition and metabolic activity of the gut microbiome, which in turn may increase the risk of certain disorders.
For the first time a team of researchers have discovered clear signs of enterovirus in acute flaccid myelitis patients, strongly suggesting that the disease is viral.
In 2018 more people received treatment for tuberculosis than ever before, largely due to improvements in detection and diagnosis, according to the latest Global Tuberculosis Report from the WHO.
Researchers have developed nanomeshes as an effective drug-delivery system for antibiotics.